Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Citigroup

Posted by Brenda Bartman on Sep 25th, 2026

Research analysts at Citigroup initiated coverage on shares of Maze Therapeutics (NASDAQ:MAZE – Get Free Report) in a note issued to investors on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $50.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 91.94% from the stock’s current price.

Other research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Maze Therapeutics in a report on Thursday. Four equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Maze Therapeutics has an average rating of “Buy” and an average target price of $63.40.

View Our Latest Report on Maze Therapeutics

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock traded down $0.16 during trading hours on Wednesday, reaching $26.05. 925,607 shares of the stock traded hands, compared to its average volume of 755,571. Maze Therapeutics has a one year low of $21.95 and a one year high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average price of $27.16 and a 200 day moving average price of $29.04.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). On average, equities research analysts predict that Maze Therapeutics will post -2.72 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the transaction, the insider owned 26,250 shares in the company, valued at approximately $717,675. The trade was a 22.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total transaction of $907,031.29. Following the transaction, the chief executive officer owned 18,151 shares in the company, valued at approximately $477,189.79. This trade represents a 65.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 191,459 shares of company stock worth $5,263,539 over the last three months. 5.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics in the second quarter valued at about $122,983,582. Alphabet Inc. purchased a new stake in shares of Maze Therapeutics during the second quarter worth about $41,435,000. TRV GP IV LLC bought a new stake in Maze Therapeutics during the 2nd quarter valued at approximately $133,502,907. Frazier Life Sciences Management L.P. raised its stake in Maze Therapeutics by 10.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares during the period. Finally, Hhlr Advisors LTD. purchased a new position in Maze Therapeutics in the 2nd quarter worth approximately $10,922,000.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

Positive Sentiment: Citigroup issued bullish coverage. A correction clarified that Citi initiated Maze Therapeutics with a “Buy” rating and a $50 price target, implying substantial upside from recent levels. Citi subsequently upgraded the stock to “Strong Buy.” Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target
Positive Sentiment: Additional analysts also see significant upside. BTIG initiated coverage with a “Buy” rating and a $50 target, while HC Wainwright reaffirmed its “Buy” rating and maintained a $110 target—more than four times the recent share price. BTIG Initiates Maze Therapeutics at Buy With $50 Price Target HC Wainwright Reaffirms Buy Rating
Positive Sentiment: Wedbush rated the company “Outperform.” The additional constructive view reinforces the broader analyst optimism surrounding Maze’s prospects. Maze Therapeutics Earns Outperform Rating from Wedbush
Neutral Sentiment: Reported short interest was zero shares. The September 24 report listed no shares sold short and a 0.0-day short-interest ratio. This could reduce evidence of bearish positioning, although the figure may reflect a reporting or data issue given the accompanying reference to a large increase in short interest. Maze Therapeutics Shares Moved, So What Is Driving Attention Now?

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.